- Denovo Biomarkers, ALS-ETF to explore personalized medicine in amyotrophic lateral sclerosis
- CVS/pharmacy's in-store fundraising campaign raises more than $5M for ALS, cystic fibrosis research
- Experimental ALS drug fails in trial
- Adherence is boosted by face-to-face contact, study finds
- CVS/pharmacy launches in-store campaign to support ALS, cystic fibrosis
PORT WASHINGTON, N.Y. — Aceto Corp. will sell an authorized generic version of a drug used to treat a rare but devastating degenerative disorder.
Aceto said it would launch the authorized generic version of Covis Pharma's Rilutek (riluzole) tablets in the 50-mg strength through its Rising Pharmaceuticals subsidiary. The drug is used to treat amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.
Sales of the drug were about $64 million in 2012, according to Aceto.